Advances in the systemic treatment of pancreatic neuroendocrine tumors

Cancer Treatment Reviews

Volumn 37, Issue 2, 2011, Pages 127-132

  Yalcin, Suayib ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Neuroendocrine; Octreotide; Pancreas; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; CHLOROZOTOCIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; EVEROLIMUS; GROWTH FACTOR; IMATINIB; INTERFERON; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PAZOPANIB; PEPTIDE; PLACEBO; PLATINUM DERIVATIVE; SOMATOSTATIN; SORAFENIB; STREPTOZOCIN; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; VATALANIB;

ABDOMINAL CRAMP; ANTIANGIOGENIC THERAPY; BONE MARROW SUPPRESSION; CANCER STAGING; CHEMOEMBOLIZATION; CHOLELITHIASIS; DEPRESSION; DIARRHEA; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOPHYSIS TUMOR; HYPOTHYROIDISM; INJECTION SITE REACTION; LIVER TOXICITY; NAUSEA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; RADIOFREQUENCY ABLATION; REVIEW; STEATORRHEA; SYSTEMIC THERAPY; TUMOR GROWTH;

HUMANS; INTERFERONS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SOMATOSTATIN;

EID: 79151469192     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.07.003     Document Type: Review

References (59)

1. Yalcin S., Oyan B., Bayraktar Y. Current medical treatment of pancreatic neuroendocrine tumors. Hepatogastroenterology 2007, 54:278-284.
2. Ehehalt F., Saeger H.D., Schmidt C.M., Grutzman R. Neuroendocrine tumors of the pancreas. Oncologist 2009, 14:454-467.
3. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
4. Vortmeyer A.O., Huang S., Lubensky I., Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004, 89:1934-1938.
5. Burnik F.S., Yalcin S. NF-kappa gene polymorphism in NET. Chemotherapy 2009. Chemotherapy 2009, 55:381-385.
6. Panzuto F., Nasoni S., Falconi M., et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005, 12:1083-1092.
7. Zikusoka M.N., Kidd M., Eick G., et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005, 104:2292-2309.
8. Halfdanarson T.R., Rabe K.G., Rubin J., et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008, 19:1727-1733.
9. Moldow R.E., Connelly R.R. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology 1968, 55:677-686.
10. Hill J.S., McPhee J.T., McDade T.P., et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009, 115:741-751.
11. Oberg K., Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005, 19:753-781.
12. Yao J.C., Eisner M.P., Leary C., et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007, 14:3492-3500.
13. Fesinmeyer M.D., Austin M.A., Li C.I., et al. Differences in survival by histological type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1766-1773.
14. Bilimoria K.Y., Bentrem D.J., Merkow R.P., et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007, 205:558-563.
15. Mansour J.C., Chen H. Pancreatic endocrine tumors. J Surg Res 2004, 120:139-161.
16. Kimura W., Kuroda A., Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991, 36:933-942.
17. Zikusoka M.N., Kidd M., Eick G., et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005, 104:2292-2309.
18. Klöppel G., Perren A., Heitz P.U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004, 1014:13-27.
19. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. In: World Health Organization International Classification of Tumours. Berlin: Springer; 2000. p. 61-8.
20. Rindi G., Klöppel G., Ahlman H., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
21. Sobin L.H., Gospodarowicz M.K., Wittekind C. UICC: TNM classification of malignant tumours 2009, Wiley-Blackwell, Oxford. 7th ed.
22. Capdevila J., Salazar R. Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Targ Oncol 2009, 4:287-296.
23. Eriksson B., Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999, 10(Suppl. 2):S31-S38.
24. Shah T., Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005, 19:617-636.
25. Arnold R., Trautmann M.E., Creutzfeldt W., et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996, 38:430-438.
26. Saltz L., Trochanowski B., Buckley M., et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993, 72:244-248.
27. Arnold R, Muller H, Schade-Brittinger C, et al. Placebo-controlled, double blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009;27:15s [Suppl., abstr. 4508].
28. Oberg K., Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol 1991, 79(Suppl. 1):74-77.
29. Pavel M.E., Baum U., Hahn E.G., et al. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006, 26:8-13.
30. Faiss S., Pape U.F., Bohmig M., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the international lanreotide and interferon alfa study group. J Clin Oncol 2003, 21:2689-2696.
31. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992, 326:519-523.
32. Moertel C.G., Johnson C.M., McKusick M.A., et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994, 120:302-309.
33. Ramanathan R.K., Cnaan A., Hahn R.G., et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern cooperative oncology group-E6282. Ann Oncol 2001, 12:1139-1143.
34. Sun W., Lipsitz S., Catalano P., et al. Eastern cooperative oncology group: Phase II/III study of doxorubicin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern cooperative oncology group study E1281. J Clin Oncol 2005, 23:4897-4904.
35. Ekeblad S., Sundin A., Janson E.T., et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13:2896-2991.
36. Kulke M.H., Hornick J.L., Frauenhoffer C., et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009, 15:338-345.
37. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastaticneu roendocrine tumors. J Clin Oncol 2006, 24:401-406.
38. Isacoff WH, Moss RA, Pecora AL, Fine RL. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol 2006;24(18S). ASCO annual meeting proceedings, part I [June 20 Suppl.].
39. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol 2005;23(16S). ASCO annual meeting proceedings, part I of II. p. 4216 [June 1 Suppl.].
40. Kulke MH, Stuart K, Earle CC. Aphase II studyof temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24(18S). ASCO annual meeting proceedings, part I [June 20 Suppl.].
41. Kulke M.H., Lens H., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
42. Raymond E, Niccoli-Sire P, Bang Y, et al. Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). In: 2010 gastrointestinal cancers symposium abstract no. 127.
43. Missiaglia E., Dalai I., Barbi S., et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28:245-255.
44. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Brit J Cancer 2006, 95:1148-1154.
45. Yao J.C., Phan A.T., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26:4311-4318.
46. Yao J.C., Lombard-Bohas C., Baudin E., et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28:69-76.
47. Yao JC, Shah M, Ito T et al. Everolimus versus placebo in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3). In: Presented at 12 world congress on gastrointestinal cancer, Barcelona, Spain, 30 June-3 July, 2010.
48. Phan AT, Yao JC, Fogelman DR, et al. A prospective multiinstitutional phase II study of GW786034(pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). ASCO 2010 abstr. 4001.
49. Hobday T, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. In: ASCO annual meeting, abstract # 4504, 2007.
50. Pavel M, Bartel C, Heuck F, et al. Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 2008;26 [Suppl., abstr. 14684].
51. Anthony L, Chester M, Michael S, et al. Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 2008;26 [Suppl., abstr. 14624].
52. Hobday T, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2006;24(18S). ASCO annual meeting proceedings part I. p. 4043 [June 20 Suppl.].
53. Gross D.J., Munter G., Bitan M., et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-related Cancer 2006, 13:535-540.
54. Rothenberg M, Tolcher A, Sarantopoulos J, et al. AMG 479 monotherapy to treat patients with advanced GI carcinoid tumors: a subset analysis from the first-in-human study. In: Gastrointestinal cancers symposium, abs. #3862009.
55. Di Cosimo S, Seoane J, Guzman M et al. Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the i{dotless}nsulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: a mechanistic based anti-tumor strategy. Proc Am Soc Clin Oncol 2005;23(16S):3112.
56. Gaur P, Samuel S, Bose D et al. Blockade of in vivo tumor growth of newly established human midgut carcinoid tumors by Src inhibition. In: ASCO gastrointestinal cancers symposium, 2009, 146.
57. Shah M, Martin E, Ellison C, et al. A phase II study of proteasome inhibitor PS-341 in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002;21 [abstr. 111].
58. Sung M, Kvols L, Wolin E, et al. Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 2008:26 [Suppl., abstr. 4611].
59. Lubner S, Chen H, Holen K, et al. A phase II clinical and biological study of lithium carbonate (Li) in patients with low-grade neuroendocrine tumors. J Clin Oncol 2009;27 [Suppl., abstr. e15662].